CLPT Quote, Financials, Valuation and Earnings

Integra LifeSciences Holdings Corp. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of -1.34%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 104.66%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 27.15%. Given that Clearpoint Neuro, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Clearpoint Neuro, Inc. is more attractive than Integra LifeSciences Holdings Corp..

Clearpoint Neuro, Inc. has a beta of 0.915, which suggesting that the stock is 8.545% less volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.536%.

Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.56x versus 0.57x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of 6.19%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 104.66%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 64.16%. Given that Clearpoint Neuro, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Clearpoint Neuro, Inc. is more attractive than InfuSystem Holdings, Inc..

Clearpoint Neuro, Inc. has a beta of 0.915, which suggesting that the stock is 8.545% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.56x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of -862.39%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat VolitionRX Ltd.'s return on equity of --.

Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 104.66%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 661.77%. Given that VolitionRX Ltd. has higher upside potential than Clearpoint Neuro, Inc., analysts believe VolitionRX Ltd. is more attractive than Clearpoint Neuro, Inc..

Clearpoint Neuro, Inc. has a beta of 0.915, which suggesting that the stock is 8.545% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.

Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.56x versus 19.79x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of 3.93%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 104.66%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 141.12%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Clearpoint Neuro, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Clearpoint Neuro, Inc..

Clearpoint Neuro, Inc. has a beta of 0.915, which suggesting that the stock is 8.545% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.56x versus 0.68x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.